Enanta Pharmaceuticals to Discuss Pipeline and Strategy at Citizens Life Sciences Conference
Event summary
- Enanta Pharmaceuticals will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026, at 10:45 a.m. ET in Miami Beach, FL.
- The event will be webcast live and archived for at least 30 days.
- Enanta's clinical programs are focused on respiratory syncytial virus (RSV) and inflammatory diseases.
- Glecaprevir, discovered by Enanta, is part of a leading HCV treatment regimen sold by AbbVie.
The big picture
Enanta Pharmaceuticals is leveraging its chemistry-driven approach to develop small molecule drugs for viral infections and immunological diseases. The company's participation in The Citizens Life Sciences Conference highlights its strategic focus on RSV and inflammatory diseases, while ongoing royalties from AbbVie's HCV treatments provide critical funding. The event offers a platform to discuss Enanta's pipeline progress and market positioning amid broader trends in biotech innovation and therapeutic development.
What we're watching
- Pipeline Progress
- How Enanta's RSV and immunology programs advance in 2026...
- Royalty Revenue
- Whether AbbVie's HCV product sales sustain Enanta's funding...
- Market Positioning
- The pace at which Enanta differentiates itself in viral and immunological treatments...
Related topics